MET-2 / NuBiyota - LARVOL DELTA

A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection. (PubMed, mBio) - "We evaluated whether a microbial consortium had similar effects to FMT on Pseudomonadota abundances and ARGs as well as obligate anaerobes and beneficial butyrate producers in individuals with high Pseudomonadota relative abundance at baseline. This study provides support for a randomized, controlled clinical trial of microbial consortia (such as MET-2) for ARO decolonization and anaerobe repletion."

Clinical • Journal • Infectious Disease • Transplantation

Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC) (clinicaltrials.gov) - P1b; N=11; Completed; Sponsor: NuBiyota; Active, not recruiting ➔ Completed; N=30 ➔ 11

Clinical • Enrollment change • Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: NuBiyota; Not yet recruiting ➔ Recruiting; Initiation date: Dec 2020 ➔ Apr 2021

Clinical • Enrollment open • Trial initiation date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression (clinicaltrials.gov) - P2; N=60; Not yet recruiting; Sponsor: NuBiyota

Clinical • New P2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry